Strategic Collaborations Alloy has an extensive partner network including 18 Fortune 50 biopharma companies and multiple strategic collaborations (Biogen, AbbVie, Voro Therapeutics, Cantai, IPI). This indicates strong affinity for joint discovery programs and potential upsell opportunities to license or expand existing engagements with large pharmaceutical players.

Platform as a Service The company markets a broad suite of discovery platforms combining in vivo and in vitro capabilities with AI/ML, plus a TCRm and AntiClastic ASO offerings. This creates multiple entry points for clients seeking either service-based discovery or licensing to integrate Alloy’s platforms into their internal pipelines.

New Targeting Capabilities Recent emphasis on masked T-cell engager therapeutics and nucleic acid targeting with novel formats suggests opportunities to cross-sell to immuno-oncology and genetic disease programs, particularly with partners aiming to reach difficult intracellular or challenging targets.

Venture Studio Synergy 82VS, Alloy’s affiliated Venture Studio, enables co-building new biotech ventures using Alloy’s core platforms. This presents a path to engage with early-stage programs and secure long-term collaboration through Equity-friendly discovery partnerships.

Geographic and Funding Potential With labs in the US and Europe and a revenue base in the tens of millions, Alloy’s global footprint and reinvestment strategy into innovation position it as a scalable partner for multinational collaborations, license deals, and expanded service agreements across regions.